NCT05881109View on ClinicalTrials.gov

Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

March 3, 2019

Study Completion Date

March 3, 2019

Conditions
Invasive Fungal Infections
Interventions
DRUG

Caspogunfin

No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).

Trial Locations (1)

Unknown

Wuhan Children's Hospital, Wuhan

All Listed Sponsors
lead

Shandong University

OTHER

NCT05881109 - Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents | Biotech Hunter | Biotech Hunter